Quidel Corporation reported the receipt of 510(k) approval from the US Food and Drug Administration (FDA) to market its Solana Influenza A+B assay in the diagnosis of Influenza A and B infections for the upcoming 2016-2017 flu season. The company will market the Solana Influenza A+B assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the diagnosis of Influenza A and B infections. The Solana Influenza A+B assay is an easy-to-use, rapid molecular diagnostic test that has superb clinical accuracy. The assay requires no upfront extraction of RNA and generates an accurate result in approximately 45 minutes. According to the company, the Solana Influenza A+B Assay, which is a novel Reverse-Transcriptase Helicase-Dependent Amplification (HDA) technology, is resident in AmpliVue molecular product line to generate a fast and accurate test result. Additionally, the Solana can process up to 12 patient samples in each 45-minute run, thereby providing time-saving workflow advantages to healthcare professionals in moderately complex settings, concluded the company.